HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma

This item is licensed under: Creative Commons Attribution-NonCommercial 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1111/cas.14449


Title: Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
Authors: Osawa, Takahiro Browse this author →KAKEN DB
Kojima, Takahiro Browse this author →KAKEN DB
Hara, Tomohiko Browse this author
Sugimoto, Mikio Browse this author →KAKEN DB
Eto, Masatoshi Browse this author →KAKEN DB
Takeuchi, Ario Browse this author →KAKEN DB
Minami, Keita Browse this author
Nakai, Yasutomo Browse this author
Ueda, Kosuke Browse this author
Ozawa, Michinobu Browse this author
Uemura, Motohide Browse this author →KAKEN DB
Miyauchi, Yasuyuki Browse this author
Ohba, Kojiro Browse this author →KAKEN DB
Suzuki, Toshiro Browse this author
Anai, Satoshi Browse this author →KAKEN DB
Shindo, Tetsuya Browse this author →KAKEN DB
Kusakabe, Naohisa Browse this author
Tamura, Keita Browse this author
Komiyama, Motokiyo Browse this author
Goto, Takayuki Browse this author →KAKEN DB
Yokomizo, Akira Browse this author →KAKEN DB
Kohei, Naoki Browse this author
Kashiwagi, Akira Browse this author
Murakami, Masaya Browse this author
Sazuka, Tomokazu Browse this author →KAKEN DB
Yasumoto, Hiroaki Browse this author →KAKEN DB
Iwamoto, Hideto Browse this author →KAKEN DB
Mitsuzuka, Koji Browse this author →KAKEN DB
Morooka, Daichi Browse this author
Shimazui, Toru Browse this author →KAKEN DB
Yamamoto, Yoshiaki Browse this author
Ikeshiro, Suguru Browse this author
Nakagomi, Hiroshi Browse this author
Morita, Ken Browse this author
Tomida, Ryotaro Browse this author
Mochizuki, Tango Browse this author
Inoue, Takamitsu Browse this author →KAKEN DB
Kitamura, Hiroshi Browse this author
Yamada, Shuhei Browse this author
Ito, Yoichi M. Browse this author
Murai, Sachiyo Browse this author
Nishiyama, Hiroyuki Browse this author →KAKEN DB
Shinohara, Nobuo Browse this author →KAKEN DB
Keywords: axitinib
metastatic
prognostic factor
renal cell carcinoma
risk model
Issue Date: Jul-2020
Publisher: John Wiley & Sons
Journal Title: Cancer science
Volume: 111
Issue: 7
Start Page: 2460
End Page: 2471
Publisher DOI: 10.1111/cas.14449
Abstract: The present study aimed to evaluate the efficacy of the real-world use of axitinib and to develop a prognostic model for stratifying patients who could derive long-term benefit from axitinib. This was a retrospective, descriptive study evaluating the efficacy of axitinib in patients with metastatic renal cell carcinoma that had been treated with 1 or 2 systemic antiangiogenic therapy regimens at 1 of 36 hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. The primary outcome was overall survival (OS). Using a split-sample method, candidate variables that exhibited significant relationships with OS were chosen to create a model. The new model was validated using the rest of the cohort. In total, 485 patients were enrolled. The median OS was 34 months in the entire study population, whereas it was not reached, 27 months, and 14 months in the favorable, intermediate, and poor risk groups, respectively, according to the new risk classification model. The following 4 variables were included in the final risk model: the disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio. The adjusted area under the curve values of the new model at 12, 36, and 60 months were 0.77, 0.82, and 0.82, respectively. The efficacy of axitinib in routine practice is comparable or even superior to that reported previously. The patients in the new model's favorable risk group might derive a long-term survival benefit from axitinib treatment.
Rights: https://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/79043
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University